Search peptides, terms, sources/
Research source · 2018

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

About this source

Kind
Research
Design
Human clinical trial
Population
Postmenopausal women from the ACTIVE trial who went on to alendronate (558 who had received abaloparatide, 581 who had received placebo)
Sample size
1139
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Extension of the ACTIVE trial: all participants received alendronate in the second phase, so the result reflects abaloparatide followed by alendronate, not abaloparatide alone. The hip-fracture comparison was a supplemental analysis.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.